Back

Impact of multimorbidity on mortality in heart failure with mildly reduced and preserved ejection fraction

11 May 2024 (11:00 - 11:45)
Organised by: Logo
Congress Presentation Part of: Chronic heart failure - epidemiology, prognosis, outcome 5 Epidemiology, Prognosis, Outcome HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Mingming Yang

Zhongda Hospital, Southeast University, Nanjing (China)

7 More presentations in this session

Presentation thumbnail
Lowest complications and total mortality with Intra-aortic balloon pump vs Impella despite adjustment for 54 variable or hospital types in patients with cardiogenic shock
Professor M. Movahed (Tucson, US)
Abstract Slides Video
Presentation thumbnail
The impact of genetic testing in dilated cardiomyopathy: are we yet in the era of precision medicine?
Doctor I. Gomes Campos (Penafiel, PT)
Abstract Slides Video
Presentation thumbnail
Characteristics and treatment of contemporary real-world patients with cardiac transthyretin amyloidosis: a retrospective, multicenter, observational study
Doctor R. Nies (Cologne, DE)
Abstract Slides Video
Presentation thumbnail
Interstitial volume overload and risk of adverse clinical events in ambulatory heart failure
Doctor J. Montiel Perez (Valencia, ES)
Abstract Slides Video
Presentation thumbnail
Kidney failure risk equation and risk of kidney and cardiovascular outcomes in patients with heart failure with reduced ejection fraction: insights from PARADIGM-HF
Doctor I. Beldhuis (Groningen, NL)
Abstract Slides Video

Access the full session

Session thumbnail
Chronic heart failure - epidemiology, prognosis, outcome 5

The Event

Event poster

Heart Failure 2024

11 May 2024 11:00 CET
You may be interested in
thumbnail
Congress Presentation
Prognostic implications of multimorbidity in patients with heart failure with mildly reduced ejection fraction
thumbnail
Congress Session
Comorbidities and heart failure therapies
thumbnail
Congress Presentation
Impact of multimorbidity on vulnerable phase outcomes in hospitalized heart failure across ejection fraction: a report from the OPPORTUNITIES registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources